PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.92%
Negative revenue growth while MRVL stands at 14.79%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-9.52%
Negative gross profit growth while MRVL is at 17.21%. Joel Greenblatt would examine cost competitiveness or demand decline.
-17.63%
Negative EBIT growth while MRVL is at 5.90%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-17.63%
Negative operating income growth while MRVL is at 5.90%. Joel Greenblatt would press for urgent turnaround measures.
-4.84%
Negative net income growth while MRVL stands at 4.77%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-2.13%
Negative EPS growth while MRVL is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
-2.52%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-2.41%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
29.35%
Dividend growth of 29.35% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
101.67%
OCF growth above 1.5x MRVL's 66.88%. David Dodd would confirm a clear edge in underlying cash generation.
341.26%
FCF growth above 1.5x MRVL's 73.11%. David Dodd would verify if the firm’s strategic investments yield superior returns.
204.26%
10Y revenue/share CAGR at 50-75% of MRVL's 399.62%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
111.21%
5Y revenue/share CAGR under 50% of MRVL's 399.62%. Michael Burry would suspect a significant competitive gap or product weakness.
120.70%
3Y revenue/share CAGR at 50-75% of MRVL's 173.24%. Martin Whitman would question if the firm lags behind competitor innovations.
37.20%
10Y OCF/share CAGR under 50% of MRVL's 2771.12%. Michael Burry would worry about a persistent underperformance in cash creation.
18.07%
Below 50% of MRVL's 2771.12%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
39.81%
3Y OCF/share CAGR under 50% of MRVL's 587.48%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
2571.27%
Net income/share CAGR above 1.5x MRVL's 119.06% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
727.64%
5Y net income/share CAGR above 1.5x MRVL's 119.06%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
129.87%
Below 50% of MRVL's 439.05%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
187.22%
Positive growth while MRVL is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
4.23%
Positive 5Y equity/share CAGR while MRVL is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
69.04%
3Y equity/share CAGR above 1.5x MRVL's 31.66%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
87.75%
Dividend/share CAGR of 87.75% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
75.60%
Dividend/share CAGR of 75.60% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
184.42%
3Y dividend/share CAGR of 184.42% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-15.08%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-3.62%
Inventory is declining while MRVL stands at 40.98%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-5.78%
Negative asset growth while MRVL invests at 9.18%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-3.10%
We have a declining book value while MRVL shows 9.12%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.46%
Our R&D shrinks while MRVL invests at 14.23%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.39%
We cut SG&A while MRVL invests at 18.10%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.